Purple Biotech Ltd.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Gil Efron
- Full Time Employees
- 9
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 4 Oppenheimer Street Rehovot Israel 7670104
- IPO Date
- Nov 20, 2015
- CIK
- 0001614744
- Website
- purple-biotech.com
- Similar Companies
- Business
- Purple Biotech Ltd. is a clinical-stage biotechnology company specializing in the development of first-in-class therapies designed to overcome tumor immune evasion and drug resistance to improve cancer treatment outcomes. The company's core oncology product pipeline includes CM24, a humanized monoclonal antibody that blocks CEACAM1 to counteract tumor immune evasion and is currently in Phase 2 clinical trials for pancreatic ductal adenocarcinoma; NT219, a novel small molecule dual inhibitor targeting insulin receptor substrate 1 and 2 (IRS1/2) and STAT3, in Phase 1/2 trials for recurrent/metastatic squamous cell carcinoma of the head and neck and colorectal adenocarcinoma; and CAPTN-3, a preclinical platform of conditionally activated tri-specific antibodies that engage T cells and natural killer cells to induce a strong localized immune response within the tumor microenvironment. CM24 is being evaluated in combination with the PD-1 inhibitor nivolumab and chemotherapy under a collaboration agreement with Bristol Myers Squibb. The company also advances the IM1240 tri-specific antibody from the CAPTN-3 platform, targeting the tumor-associated antigen 5T4, with plans to submit an Investigational New Drug (IND) application in 2026. Major recent developments include successful Phase 2 clinical trial results for CM24 in pancreatic cancer, demonstrating up to a 79% reduction in risk of death for biomarker-selected patients and signaling progress toward a Phase 2b study supported by biomarker stratification. NT219 has completed dose escalation and is advancing into a Phase 2 study in head and neck cancer in collaboration with the University of Colorado, with patient enrollment underway as of early 2025. CAPTN-3 achieved a manufacturing milestone by producing commercially viable yields of IM1240, validating the platform's scalability and competitive positioning for future clinical development. The company has significantly reduced operating losses and R&D expenses, securing $4.3 million in additional funding to extend its operational runway. Purple Biotech was formerly known as Kitov Pharma Ltd before changing its name in December 2020. Purple Biotech operates primarily in Israel, headquartered in Rehovot, with a focus on precision oncology therapies leveraging tumor microenvironment biology. Founded in 1968, the company engages in global clinical collaborations and targets cancer patient populations needing improved durable therapies. It maintains a lean organizational structure with a strategic focus on clinical development and commercialization partnerships for its innovative immuno-oncology platforms. The company is publicly traded on NASDAQ and the Tel Aviv Stock Exchange under the ticker PPBT.
Purple Biotech Regains Compliance with Nasdaq
Purple Biotech Announces CEO Transition
Purple Biotech Announces Plan to Implement ADS Ratio Change
Short Interest in Purple Biotech Ltd. Sponsored ADR (NASDAQ:PPBT) Expands By 29.9%
Purple Biotech (NASDAQ:PPBT) Shares to Reverse Split on Monday, March 2nd
Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress
Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update
Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform
Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification
Purple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants
Purple Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Purple Biotech Reports Second Quarter 2025 Financial Results
Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025
Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress
Purple Biotech Reports First Quarter 2025 Financial Results
Purple Biotech Appoints Shai Lankry as Chief Financial Officer
Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers
Purple Biotech Reports Fourth Quarter and Full-Year 2024 Financial Results
Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial
Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares